Chromadex Corp. revenue decreases to $22.56 million in quarter ended Mar 31, 2023 from previous quarter
Key fundamental financials
loss of $1.90 million
Revenue of $22.56 million
Current Reporting
Revenue
Net Income
Profit/Loss
Mar 2023
$22.56 million
$1.90 million
loss
Sep 2022
$17,063
$985
loss
Jun 2022
$16.73 million
$6.40 million
loss
Chromadex Corp. [CDXC] has reported $1.90 million loss for the fiscal quarter ending Mar 31, 2023.
Revenue for the quarter was $22.56 million with operating income of $1.97 million.
The Irvine, California (CA)-based company operating in the medicinal chemicals & botanical products sector has total shareholders equity of $28.02 million.